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Fluorescent molecular tomography (FMT) is a noninvasive biomedical optical imaging that enables 3-
dimensional quantitative determination of fluorochromes distributed in biological tissues. There are three
methods for imaging large volume tissues based on different light sources: (a) using a light source of
constant intensity, through a continuous or constant wave, (b) using a light source that is intensity
modulated with a radio frequency (RF), and (c) using ultrafast pulses in the femtosecond range. In this
study, we have developed a frequency domain fluorescent molecular tomographic system based on the
heterodyne technique, using a single source and detector pair that can be used for small animal imaging.
In our system, the intensity of the laser source is modulated with a RF frequency to produce a diffuse
photon density wave in the tissue. The phase of the diffuse photon density wave is measured by comparing
the reference signal with the signal from the tissue using a phasemeter. The data acquisition was
performed by using a Labview program. 
The results suggest that we can measure the phase change from the heterogeneous inside tissue.
Combined with fiber optics and filter sets, the system can be used to sensitively image the targeted
fluorescent molecular probes, allowing the detection of cancer at an early stage. 
We used the system to detect the tumor-targeting molecular probe Alexa Fluor 680 and Alexa Fluor 750
bombesin peptide conjugates in phantoms as well as mouse tissues. We also developed and evaluated
fluorescent Bombesin (BBN) probes to target gastrin-releasing peptide (GRP) receptors for optical
molecular imaging. GRP receptors are over-expressed in several types of human cancer cells, including
breast, prostate, small cell lung, and pancreatic cancers. BBN is a 14 amino acid peptide that is an
analogue to human gastrin-releasing peptide that binds specifically to GRPr receptors. BBN conjugates are
significant in cancer detection and therapy. The optical molecular probe AF750 BBN peptide exhibits
optimal pharmacokinetic properties for targeting GRPr in mice. Fluorescent microscopic imaging of the
molecular probe in PC-3 prostate and T-47D breast cancer cell lines indicated specific uptake,
internalization, and receptor blocking of these probes. In vivo investigations in severely compromised
immunodeficient (SCID) mice bearing xenografted PC-3 prostate and T47-D breast cancer lesions
demonstrated the ability of this new molecular probe to specifically target tumor tissue with high selectively
and affinity. 
